Utah's hospital scene is increasingly controlled by just a handful of big systems, and that tightening grip is changing what care looks like for regular people. A growing share of communities now have only one realistic option for inpatient treatment, and a new analysis suggests that kind of dominance often comes with a familiar side effect: higher bills and fewer choices. State lawmakers, regulators and health systems are staring down a tough question about how hard to push back on the next round of deals.
What the Yale data shows
The Health Care Affordability Lab at Yale recently rolled out an interactive hospital-markets tool that defines local markets by a 30-minute travel time and highlights where ownership is heavily concentrated. According to data from the lab and as reported by Axios, about 61.7% of the 47 Utah hospitals the lab analyzed are in concentrated ownership markets or effectively operate as monopolies. The lab's map, available through the Health Care Affordability Lab at Yale, lets users zoom into counties and see which hospitals are the only nearby option.
Why consolidation matters
Federal reviews and academic studies have been sounding the alarm on consolidation for years. A January 2025 HHS synthesis, summarized by the Bipartisan Policy Center, found that horizontal hospital mergers in already concentrated markets can raise hospital prices by roughly 6% to 65%. At the same time, national spending data from KFF shows hospital care alone accounted for about 40% of the growth in U.S. health spending between 2022 and 2024. Put together, those trends turn market maps into more than academic curiosities, since they can flag places where patients and payers may feel a financial hit after a merger closes.
Local history: big deals and enforcement
Utah has already seen how big deals and federal enforcement can redraw the map along the Wasatch Front. Salt Lake City-based Intermountain Healthcare completed its merger with Colorado-based SCL Health in 2022, expanding Intermountain's regional footprint. That same year, in June 2022, the Federal Trade Commission sued to block HCA Healthcare's proposed purchase of five Steward hospitals in Utah. The FTC argued the deal would wipe out a low-cost competitor in markets where many Utahns already depend on a small number of hospitals, a factor regulators say is central when evaluating patient choice and price pressure.
What it means for patients and doctors
Consolidation does not just play out in hospital towers; it reaches into exam rooms, too. When hospital systems buy physician practices or convert independent outpatient clinics into hospital departments, the very same service can start to cost more, and patients can be stuck with higher out-of-pocket bills. A national study in JAMA Health Forum found that primary-care doctors affiliated with hospitals or private-equity firms negotiated higher prices for office visits than independent practices, suggesting consolidation often spills over into the everyday doctor visit. For Utah residents, that can mean familiar local clinics stay open, but the price tag attached to a routine appointment quietly climbs.
Legal and policy stakes
Mergers are not a foregone conclusion. Federal antitrust actions can and do stop some transactions, but historically only a small fraction of deals face that kind of challenge. National coverage notes roughly 1,300 hospital mergers over the past two decades and that the FTC has challenged only a handful, a gap critics say leaves many local markets without serious scrutiny. Policymakers in Utah are likely to lean on the Yale lab's maps and recent federal analyses as they debate whether to push for tougher state-level review, site-neutral payment rules, or other tools aimed at protecting competition.
What to watch next
The Yale Health Care Affordability Lab says its market explorer is meant to be a long-term resource for regulators, researchers and lawmakers who are tracking consolidation over time, and its Utah findings are almost certain to surface in upcoming policy fights. If Utah moves toward stronger state oversight, the first audiences will be state lawmakers, the attorney general's office and consumer advocates, while federal enforcers remain the backstop for deals with interstate implications. For now, patients and employers across the state are waiting to see whether competition can return to local hospital markets or whether a few big systems keep tightening their grip.
